MX357998B - Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo. - Google Patents

Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.

Info

Publication number
MX357998B
MX357998B MX2015003641A MX2015003641A MX357998B MX 357998 B MX357998 B MX 357998B MX 2015003641 A MX2015003641 A MX 2015003641A MX 2015003641 A MX2015003641 A MX 2015003641A MX 357998 B MX357998 B MX 357998B
Authority
MX
Mexico
Prior art keywords
acid
patients
renal failure
acute
chronic
Prior art date
Application number
MX2015003641A
Other languages
English (en)
Other versions
MX2015003641A (es
Inventor
Antonio Hernandez Miramontes Jorge
Alberto Hernandez Villanueva Jorge
Original Assignee
Antonio Hernandez Miramontes Jorge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56234463&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357998(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antonio Hernandez Miramontes Jorge filed Critical Antonio Hernandez Miramontes Jorge
Priority to MX2015003641A priority Critical patent/MX357998B/es
Priority to SG11201705163XA priority patent/SG11201705163XA/en
Priority to EP15886606.1A priority patent/EP3219315B1/en
Priority to EA201700339A priority patent/EA036702B1/ru
Priority to AU2015387986A priority patent/AU2015387986B2/en
Priority to JP2017541850A priority patent/JP6771191B2/ja
Priority to PCT/MX2015/000144 priority patent/WO2016153331A1/es
Priority to KR1020177022643A priority patent/KR102057555B1/ko
Priority to TN2017000257A priority patent/TN2017000257A1/en
Priority to CN201580072466.5A priority patent/CN108024981B/zh
Priority to CA2972889A priority patent/CA2972889C/en
Priority to US15/547,620 priority patent/US10688068B2/en
Priority to MYPI2017702409A priority patent/MY173111A/en
Priority to PE2017001076A priority patent/PE20180228A1/es
Priority to NZ733186A priority patent/NZ733186A/en
Priority to ES15886606T priority patent/ES2850998T3/es
Priority to BR112017017189-9A priority patent/BR112017017189A2/pt
Priority to CR20170320A priority patent/CR20170320A/es
Publication of MX2015003641A publication Critical patent/MX2015003641A/es
Priority to CL2017001262A priority patent/CL2017001262A1/es
Priority to PH12017501157A priority patent/PH12017501157B1/en
Priority to GT201700149A priority patent/GT201700149A/es
Priority to DO2017000161A priority patent/DOP2017000161A/es
Priority to CONC2017/0007046A priority patent/CO2017007046A2/es
Priority to IL253480A priority patent/IL253480B/en
Priority to ECIEPI201756559A priority patent/ECSP17056559A/es
Publication of MX357998B publication Critical patent/MX357998B/es
Priority to HK18109048.3A priority patent/HK1249426A1/zh
Priority to US16/699,207 priority patent/US20200138755A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/20—Sebacic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Actualmente el tratamiento para pacientes con enfermedad renal terminal (estadio V) consiste en terapia renal sustitutiva (hemodiálisis, diálisis peritoneal o transplante renal); extraordinariamente costosa que conlleva una pobre calidad de vida. Nuestro invento es una mezcla de ácidos carboxílicos: ácido cítrico, ácido succínico, ácido fumárico y ácido málico, y cualesquiera de sus combinaciones posibles. Dicho producto se utiliza preferentemente vía oral o también vía intravenosa, en el tratamiento de pacientes con insuficiencia renal crónica, hiperamonemia o condiciones humanas que cursen con balance nitrogenado negativo. Este producto es benéfico para disminuir los valores séricos de urea y de amonio sérico, a la vez que por transaminación del oxalacelato formado vía succinato, fumarato y malato, promueve la biosíntesis de aminoácidos no esenciales; por transminación del alfa ceto glutarato formado vía citrato, genera ácido glutámico y los aminoácidos relacionádos al mismo como glutamina. Este tratamiento previene, preserva e inclusive mejora la función renal. En otros pacientes retarda el deterioro de la función renal y la imperiosa necesidad del tratamiento renal sustitutivo. En otros más, se utiliza como tratamiento complementario al tratamiento renal sustitutivo para mejorar la calidad de vida del paciente y mejorar los parámetros laboratoriales.
MX2015003641A 2015-03-20 2015-03-20 Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo. MX357998B (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
MX2015003641A MX357998B (es) 2015-03-20 2015-03-20 Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
CR20170320A CR20170320A (es) 2015-03-20 2015-11-04 Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
MYPI2017702409A MY173111A (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
NZ733186A NZ733186A (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
EA201700339A EA036702B1 (ru) 2015-03-20 2015-11-04 Смесь карбоновых кислот для лечения пациентов с почечной недостаточностью
AU2015387986A AU2015387986B2 (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
JP2017541850A JP6771191B2 (ja) 2015-03-20 2015-11-04 腎不全患者治療のためのカルボン酸混合物
PCT/MX2015/000144 WO2016153331A1 (es) 2015-03-20 2015-11-04 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal
KR1020177022643A KR102057555B1 (ko) 2015-03-20 2015-11-04 신부전 환자를 치료하기 위한 카복실산 혼합물
TN2017000257A TN2017000257A1 (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
CN201580072466.5A CN108024981B (zh) 2015-03-20 2015-11-04 一种治疗肾病患者的羧酸组合物
CA2972889A CA2972889C (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
US15/547,620 US10688068B2 (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
SG11201705163XA SG11201705163XA (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
PE2017001076A PE20180228A1 (es) 2015-03-20 2015-11-04 Mezcla de acidos carboxilicos para tratar pacientes con insuficiencia renal
EP15886606.1A EP3219315B1 (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure
ES15886606T ES2850998T3 (es) 2015-03-20 2015-11-04 Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
BR112017017189-9A BR112017017189A2 (pt) 2015-03-20 2015-11-04 mistura de ácidos carboxílicos para o tratamento de pacientes com insuficiência renal
CL2017001262A CL2017001262A1 (es) 2015-03-20 2017-05-17 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal.
PH12017501157A PH12017501157B1 (en) 2015-03-20 2017-06-20 Mixture of carboxylic acids for treating patients with kidney failure
GT201700149A GT201700149A (es) 2015-03-20 2017-06-27 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal
DO2017000161A DOP2017000161A (es) 2015-03-20 2017-07-06 Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
CONC2017/0007046A CO2017007046A2 (es) 2015-03-20 2017-07-13 Mezcla de ácidos carboxilicos para tratar pacientes con insuficiencia renal
IL253480A IL253480B (en) 2015-03-20 2017-07-13 A mixture of carboxylic acids for the treatment of patients with renal failure
ECIEPI201756559A ECSP17056559A (es) 2015-03-20 2017-08-28 Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
HK18109048.3A HK1249426A1 (zh) 2015-03-20 2018-07-12 一種治療腎病患者的羧酸組合物
US16/699,207 US20200138755A1 (en) 2015-03-20 2019-11-29 Mixture of carboxylic acids for treating patients with kidney failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015003641A MX357998B (es) 2015-03-20 2015-03-20 Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.

Publications (2)

Publication Number Publication Date
MX2015003641A MX2015003641A (es) 2016-04-08
MX357998B true MX357998B (es) 2018-07-11

Family

ID=56234463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003641A MX357998B (es) 2015-03-20 2015-03-20 Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.

Country Status (26)

Country Link
US (2) US10688068B2 (es)
EP (1) EP3219315B1 (es)
JP (1) JP6771191B2 (es)
KR (1) KR102057555B1 (es)
CN (1) CN108024981B (es)
AU (1) AU2015387986B2 (es)
BR (1) BR112017017189A2 (es)
CA (1) CA2972889C (es)
CL (1) CL2017001262A1 (es)
CO (1) CO2017007046A2 (es)
CR (1) CR20170320A (es)
DO (1) DOP2017000161A (es)
EA (1) EA036702B1 (es)
EC (1) ECSP17056559A (es)
ES (1) ES2850998T3 (es)
GT (1) GT201700149A (es)
HK (1) HK1249426A1 (es)
IL (1) IL253480B (es)
MX (1) MX357998B (es)
MY (1) MY173111A (es)
NZ (1) NZ733186A (es)
PE (1) PE20180228A1 (es)
PH (1) PH12017501157B1 (es)
SG (1) SG11201705163XA (es)
TN (1) TN2017000257A1 (es)
WO (1) WO2016153331A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193648A1 (ja) * 2017-04-18 2018-10-25 国立大学法人東北大学 アルカリ性化剤による血液浄化
JP7219898B2 (ja) * 2017-04-18 2023-02-09 国立大学法人東北大学 アルカリ性化剤による血液浄化
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
WO2020080499A1 (ja) * 2018-10-17 2020-04-23 国立大学法人東北大学 新規医薬組成物
CN109125310A (zh) * 2018-11-06 2019-01-04 河北工业大学 琥珀酸在抑制Kv10.1离子通道活性中的应用和药物
EP3976559A4 (en) 2019-05-30 2023-06-21 Koch Agronomic Services, LLC FOLIAR SOLUTIONS OF MICRONUTRIENTS
US11666548B2 (en) * 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
CN115414383A (zh) * 2022-10-14 2022-12-02 青岛普瑞森医药科技有限公司 血液透析浓缩液及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475031A (en) * 1993-09-03 1995-12-12 Livingston; William H. Discovery of a valuable property for succinic acid and other intermediary metabolites
US5500232A (en) * 1994-10-06 1996-03-19 Bristol-Myers Squibb Company Calcium fortified beverages
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
EP0938849A1 (en) 1998-02-18 1999-09-01 Quest International B.V. A composition with a fresh, fruit like taste
US6288116B1 (en) * 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
AU7032700A (en) * 1999-10-12 2001-04-23 Meiji Seika Kaisha Ltd. Low potassium juice, method for producing thereof and food containing the same
AU2002211770A1 (en) * 2000-10-16 2002-04-29 Pepsico, Inc. Calcium-supplemented beverages and method of making same
US20030211204A1 (en) * 2002-05-10 2003-11-13 Fields Christine C. Method of preparing beverages and beverage concentrates nutritionally supplemented with minerals
US20090186127A1 (en) * 2004-12-15 2009-07-23 Krumhar Kim C Energy drink compositions
BRPI0602825A2 (pt) * 2006-06-23 2012-04-24 Rhodia Br Ltda formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente
US20080058421A1 (en) 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
CN101568334A (zh) * 2006-12-12 2009-10-28 味之素株式会社 铁代谢改善剂
JP5592609B2 (ja) * 2006-12-12 2014-09-17 エイワイファーマ株式会社 鉄代謝改善剤
US20080226799A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Diet Cola Beverages
BRPI0816066A2 (pt) * 2007-08-31 2017-05-02 C B Fleet Company Incorporated método de prevenção de nefrocalcinose
NZ595867A (en) * 2009-05-15 2015-05-29 Biocepta Corp Compositions suitable for the topical treatment of fungal infections of the skin and nails
NL2009407C2 (en) 2012-09-03 2014-03-04 Dutch Renewable Energy B V Antimicrobial composition.

Also Published As

Publication number Publication date
GT201700149A (es) 2018-10-25
US20180000764A1 (en) 2018-01-04
EA036702B1 (ru) 2020-12-09
CA2972889C (en) 2019-04-23
MY173111A (en) 2019-12-27
JP6771191B2 (ja) 2020-10-21
CO2017007046A2 (es) 2018-01-05
IL253480A0 (en) 2017-09-28
PH12017501157A1 (en) 2017-11-27
US10688068B2 (en) 2020-06-23
SG11201705163XA (en) 2017-07-28
NZ733186A (en) 2018-09-28
JP2018505191A (ja) 2018-02-22
EP3219315A1 (en) 2017-09-20
AU2015387986A1 (en) 2017-07-13
EP3219315A4 (en) 2017-12-06
IL253480B (en) 2020-05-31
ECSP17056559A (es) 2017-10-31
DOP2017000161A (es) 2017-08-31
BR112017017189A2 (pt) 2018-04-03
CN108024981A (zh) 2018-05-11
CN108024981B (zh) 2021-07-20
PE20180228A1 (es) 2018-01-31
EP3219315B1 (en) 2020-09-02
KR102057555B1 (ko) 2019-12-19
EA201700339A1 (ru) 2018-02-28
HK1249426A1 (zh) 2018-11-02
ES2850998T3 (es) 2021-09-02
WO2016153331A1 (es) 2016-09-29
US20200138755A1 (en) 2020-05-07
CR20170320A (es) 2017-08-14
TN2017000257A1 (en) 2018-10-19
KR20170104575A (ko) 2017-09-15
CL2017001262A1 (es) 2017-09-29
CA2972889A1 (en) 2016-09-29
PH12017501157B1 (en) 2017-11-27
AU2015387986B2 (en) 2018-12-20
MX2015003641A (es) 2016-04-08

Similar Documents

Publication Publication Date Title
MX357998B (es) Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
PH12013502027A1 (en) Nutritional compositions having alpha-hica and alpha-ketoglutarate
MX2014003676A (es) Proteinas de doble funcion para el tratamiento de trastornos metabolicos.
PH12020500321A1 (en) Amino acid compositions for the treatment of liver disease
CA3010708A1 (en) Methods of administering hepcidin
NZ599442A (en) Allergy treatment using acid treated aqueous whey protein extract
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
MX2009013937A (es) Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
CR20210616A (es) Formas de sales cristalinas de un inhibidor de cinasas
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2018006508A (es) Bebida lechosa, método para producir lechosa, y método para mejorar el sabor de bebida lechosa.
WO2012133746A3 (ja) Ｌ－アルギニンを含む流動性栄養組成物及びその製造方法
JP6234413B2 (ja) カルシウム強化醤油調味料
MX2018000613A (es) Procedimiento para la preparacion de un producto fermentado de la leche.
WO2014153381A8 (en) Alpha-lactalbumin enriched whey protein compositions and methods of making and using them
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EP3272734A8 (en) Ahu377 crystal form, preparation method and use thereof
AU2014239483B9 (en) White mold cheese and method for producing same
MX2021015767A (es) Metodo para estabilizar el ph de una composicion acuosa que comprende un farmaco.
MX2016016313A (es) Sumplemento alimenticio a base de ferulato de etilo.
MX364490B (es) Composición farmacéutica para el mejoramiento de la condición general de enfermos crónicos con estados de pérdida de energía y proteínas.
CN109430653A (zh) 一种含有氨基酸的乳饮料组合物
UA105536U (uk) Спосіб лікування діастолічної дисфункції серця у хворих на цукровий діабет 2 типу, які перенесли не-q-інфаркт міокарда
UA108512U (uk) Поживне середовище с17в для індукції новоутворень в культурі пиляків пшениці твердої in vitro
RU2012113227A (ru) Способ коррекции гипергликемии галеновым препаратом бархата амурского

Legal Events

Date Code Title Description
FG Grant or registration